May 08, 2018
WELLESLEY, Mass., May 08, 2018–Changing habits, high rates of malnutrition and government goals of eradicating disease are all helping to drive growth of the global clinical nutrition market, according to a report by BCC Research.
The industry is expected to see a compound annual growth rate (CAGR) of 4.8% through 2022, when it could be worth $60.8 billion, according to the report Clinical Nutrition: Global Markets to 2022.
Major players in the market include Nestle, Danone, Abbott Laboratories, Mead Johnson Nutrition, Fresenius Co., Baxter International, Perrigo Co., B. Braun Medical Inc., The Kraft Heinz Co., Hospira/Pfizer, Otsuka Pharmaceutical Co., Atrium and Lonza Inc.
“Studies show that changing lifestyle habits, especially eating habits, play a major role in the reduction of rapidly-growing chronic diseases such as heart disease, obesity, cancer and diabetes,” said Robert G. Hunter, BCC Research senior editor, healthcare. “Clinical nutrition is used to improve the overall health of patients with a wide range of conditions, and making changes in the diet can help prevent and treat these conditions.”
Malnourishment Remains a Major Global Problem
Despite worldwide increases in obesity, global malnourishment continues to be a problem, the report notes. Almost 2 billion people—nearly a quarter of the world’s population—suffer from malnourishment. Of 667 million children worldwide under the age of 5, 159 million are termed “stunted” and another 52 million are deemed “wasted.” In Asia, as much as 70% of the elderly who are hospitalized suffer from malnourishment; even in the U.K. that number can reach 60%.
Editors/reporters requesting analyst interviews should contact email@example.com.